News & Stories

NurOwn AdComm Comments due 9/20!

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets on Sept. 27 in open session to discuss and make recommendations on a biologics license application from BrainStorm Therapeutics, Inc. for debamestrocel (also known as NurOwn.)

The Advisory Committee makes expert recommendations to the FDA. Members of the public are invited to leave comments for the Advisory Committee by Sept. 20. For more information or to leave a public comment, visit:

Share This Page: